[go: up one dir, main page]
More Web Proxy on the site http://driver.im/
This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!
Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2016 1
2017 1
2018 1
2019 2
2020 1
2021 1
2023 1
2024 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

9 results

Results by year

Filters applied: . Clear all
The following term was not found in PubMed: Odzijewicz
Page 1
Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials.
Maurer M, Ensina LF, Gimenez-Arnau AM, Sussman G, Hide M, Saini S, Grattan C, Fomina D, Rigopoulos D, Berard F, Canonica GW, Rockmann H, Irani C, Szepietowski JC, Leflein J, Bernstein JA, Peter JG, Kulthanan K, Godse K, Ardusso L, Ukhanova O, Staubach P, Sinclair R, Gogate S, Thomsen SF, Tanus T, Ye YM, Burciu A, Barve A, Modi D, Scosyrev E, Hua E, Letzelter K, Varanasi V, Patekar M, Severin T; PEARL-1 and PEARL-2 trial investigators. Maurer M, et al. Lancet. 2024 Jan 13;403(10422):147-159. doi: 10.1016/S0140-6736(23)01684-7. Epub 2023 Nov 23. Lancet. 2024. PMID: 38008109 Clinical Trial.
Above 40% of Polish children and young adults with type 1 diabetes achieve international HbA1c target - results of a nationwide cross-sectional evaluation of glycemic control: The PolPeDiab HbA1c study.
Szadkowska A, Baranowska-Jaźwiecka A, Michalak A, Jarosz-Chobot P, Myśliwiec M, Głowińska-Olszewska B, Szypowska A, Nazim J, Mazur A, Szalecki M, Skowrońska B, Kucharska-Zubkiewicz A, Beń-Skowronek I, Walczak M, Klupa T, Wolnik B, Zozulińska-Ziółkiewicz D, Młynarski W; PolPeDiab HbA1c Study Group. Szadkowska A, et al. Pediatr Diabetes. 2021 Nov;22(7):1003-1013. doi: 10.1111/pedi.13250. Epub 2021 Aug 4. Pediatr Diabetes. 2021. PMID: 34351670
Characteristics of Patients with Generalized Pustular Psoriasis: A Report of the Polish Generalized Pustular Psoriasis Group.
Kołt-Kamińska M, Marek-Józefowicz L, Krajewski P, Nowowiejska J, Siekierko A, Duchnik E, Jóźwicka K, Kiedrowicz M, Mleczko M, Arasiewicz H, Kucharczyk M, Owczarek W, Walecka I, Szepietowski JC, Flisiak I, Lesiak A, Narbutt J, Marchlewicz M, Owczarczyk-Saczonek A, Krasowska D, Kręcisz B, Reich A. Kołt-Kamińska M, et al. Dermatol Ther (Heidelb). 2024 Dec;14(12):3379-3393. doi: 10.1007/s13555-024-01306-w. Epub 2024 Nov 21. Dermatol Ther (Heidelb). 2024. PMID: 39572507 Free PMC article.
Effectiveness and safety of vedolizumab in inflammatory bowel disease patients aged 60 and over: an observational multicenter UK experience.
Ibraheim H, Samaan MA, Srinivasan A, Brain O, Digby-Bell J, Irving PM, Norman I, Jawad I, Biedermann J, Ibarra A, Kok KB, Parkes G, Rimmer J, Compot E, Parkes M, Segal J, Oppong P, Hart A, Hayee B, Powell N. Ibraheim H, et al. Ann Gastroenterol. 2020 Mar-Apr;33(2):170-177. doi: 10.20524/aog.2020.0447. Epub 2020 Jan 7. Ann Gastroenterol. 2020. PMID: 32127738 Free PMC article.